Hemangeol Patent Expiration

Hemangeol is a drug owned by Pierre Fabre Medicament. It is protected by 2 US drug patents filed from 2014 to 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 16, 2028. Details of Hemangeol's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338489 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Oct, 2028

(4 years from now)

Active
US8987262 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Oct, 2028

(4 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Hemangeol's patents.

Given below is the list of recent legal activities going on the following patents of Hemangeol.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 28 May, 2024 US8338489
Payment of Maintenance Fee, 8th Year, Large Entity 28 May, 2020 US8338489
Patent Issue Date Used in PTA Calculation 25 Dec, 2012 US8338489
Recordation of Patent Grant Mailed 25 Dec, 2012 US8338489
Issue Notification Mailed 05 Dec, 2012 US8338489
Dispatch to FDC 29 Nov, 2012 US8338489
Application Is Considered Ready for Issue 19 Nov, 2012 US8338489
Issue Fee Payment Verified 16 Nov, 2012 US8338489
Response to Reasons for Allowance 16 Nov, 2012 US8338489
Issue Fee Payment Received 16 Nov, 2012 US8338489


FDA has granted several exclusivities to Hemangeol. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Hemangeol, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Hemangeol.

Exclusivity Information

Hemangeol holds 3 exclusivities. All of its exclusivities have expired in 2021. Details of Hemangeol's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 14, 2017
Orphan Drug Exclusivity(ODE) Mar 14, 2021
Orphan Drug Exclusivity(ODE-62) Mar 14, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Hemangeol's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Hemangeol's generic, the next section provides detailed information on ongoing and past EP oppositions related to Hemangeol patents.

Hemangeol's Oppositions Filed in EPO

Hemangeol has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 09, 2012, by Infectopharm Arzneimittel Und Consilium Gmbh. This opposition was filed on patent number EP08838691A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP08838691A Mar, 2012 Infectopharm Arzneimittel und Consilium GmbH Opposition rejected


US patents provide insights into the exclusivity only within the United States, but Hemangeol is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Hemangeol's family patents as well as insights into ongoing legal events on those patents.

Hemangeol's Family Patents

Hemangeol has patent protection in a total of 32 countries. It's US patent count contributes only to 14.0% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Hemangeol.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Hemangeol's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 16, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Hemangeol Generics:

Propranolol Hydrochloride is the generic name for the brand Hemangeol. 43 different companies have already filed for the generic of Hemangeol, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Hemangeol's generic

How can I launch a generic of Hemangeol before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Hemangeol's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Hemangeol's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Hemangeol -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
4.28 mg/mL 21 Jul, 2022 1 16 Oct, 2028

Alternative Brands for Hemangeol

Hemangeol which is used for treating hemangioma, including infantile hemangioma., has several other brand drugs using the same active ingredient (Propranolol Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Ani Pharms
Innopran Xl


Apart from brand drugs containing the same ingredient, some generics have also been filed for Propranolol Hydrochloride, Hemangeol's active ingredient. Check the complete list of approved generic manufacturers for Hemangeol





About Hemangeol

Hemangeol is a drug owned by Pierre Fabre Medicament. It is used for treating hemangioma, including infantile hemangioma. Hemangeol uses Propranolol Hydrochloride as an active ingredient. Hemangeol was launched by Pierre Fabre in 2014.

Approval Date:

Hemangeol was approved by FDA for market use on 14 March, 2014.

Active Ingredient:

Hemangeol uses Propranolol Hydrochloride as the active ingredient. Check out other Drugs and Companies using Propranolol Hydrochloride ingredient

Treatment:

Hemangeol is used for treating hemangioma, including infantile hemangioma.

Dosage:

Hemangeol is available in solution form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
4.28MG/ML SOLUTION Prescription ORAL